A Safety and Tolerability Study of Jaktinib (NCT05279001) | Clinical Trial Compass
UnknownPhase 1
A Safety and Tolerability Study of Jaktinib
United States26 participantsStarted 2024-07-01
Plain-language summary
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
* Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
* At least 18 years of age.
* ECOG PS 0, 1, or 2.
* Expected life expectancy is greater than 24 weeks.
Exclusion Criteria:
* Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
* Major surgery or radiation therapy within 28 days prior to initiation of study drug.
* With suspected allergies to jaktinib or its excipient.
* Another clinical trial of a new drug or medical instrument within 3 months before screening.
* Females who are pregnant, currently breastfeeding, planning to become pregnant.
* Unable to adopt effective contraceptive methods during the study.
What they're measuring
1
Safety of jaktinib hydrochloride tablets
Timeframe: At least 24 weeks, up to approximately 1 year for follow-up
2
Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets